Campbell & CO Investment Adviser LLC Takes $2.75 Million Position in Insmed, Inc. $INSM

Campbell & CO Investment Adviser LLC bought a new stake in shares of Insmed, Inc. (NASDAQ:INSM) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 19,060 shares of the biopharmaceutical company’s stock, valued at approximately $2,745,000.

Other institutional investors have also bought and sold shares of the company. Stone House Investment Management LLC bought a new stake in Insmed during the third quarter valued at about $29,000. MassMutual Private Wealth & Trust FSB grew its position in shares of Insmed by 59.6% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares in the last quarter. Hilltop National Bank bought a new stake in Insmed during the 2nd quarter valued at approximately $28,000. ORG Partners LLC raised its stake in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in Insmed in the 2nd quarter worth approximately $33,000.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citigroup reaffirmed an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Truist Financial set a $205.00 target price on shares of Insmed in a research note on Monday. TD Cowen reduced their price target on shares of Insmed from $269.00 to $241.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Cowen set a $241.00 price objective on shares of Insmed in a report on Thursday, December 18th. Finally, Jefferies Financial Group set a $269.00 price objective on Insmed in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.77.

Insmed Stock Performance

NASDAQ INSM opened at $161.42 on Friday. The business’s 50 day moving average price is $187.73 and its 200-day moving average price is $153.96. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The company has a market cap of $34.43 billion, a P/E ratio of -26.08 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the prior year, the business earned ($1.27) earnings per share. The firm’s quarterly revenue was up 52.4% compared to the same quarter last year. Sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Activity

In other Insmed news, COO Roger Adsett sold 2,059 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $358,616.03. Following the completion of the sale, the chief operating officer owned 107,601 shares of the company’s stock, valued at $18,740,866.17. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sara Bonstein sold 1,447 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $252,023.99. Following the transaction, the chief financial officer owned 80,506 shares of the company’s stock, valued at $14,021,730.02. This trade represents a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 286,100 shares of company stock worth $52,595,894 over the last 90 days. Insiders own 3.00% of the company’s stock.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.